arrow
N

Nicholas Roubinis

takeda pharmaceutical company ltd.
H指数:1
被引数:31

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program

疫苗病毒血症、减毒株回复和安全性表征:TAK-003登革热疫苗临床开发项目的综合结果

Vaccine
IF3.5
2026-07-012
OAAI
Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial

对来自非登革热流行区的成人接种四价登革热疫苗(TAK-003)后的体液和细胞免疫反应:一项开放标签二期临床试验

Vaccine
IF3.5
2026-04-020
OAAI
Corrigendum to “Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine” [Vaccine 62 (2025) 127558]

勘误: “活减毒四价登革热疫苗(TAK-003)与重组九价人乳头瘤病毒疫苗联合接种的免疫原性和安全性” [Vaccine 62 (2025) 127558]

Vaccine
IF3.5
2025-10-080
PRE
Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine

四价减毒活登革热疫苗(TAK-003)与重组九价人乳头瘤病毒疫苗同时接种时的免疫原性和安全性

Vaccine
IF3.5
2025-10-060
OAAI
Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine

四价减毒活登革热疫苗(TAK-003)与重组九价人乳头瘤病毒疫苗联合接种的免疫原性和安全性

Vaccine
IF3.5
2025-07-310
OA
Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific

在拉丁美洲和亚太地区开展长期随机登革热疫苗试验中的发热监测所面临的运营挑战与经验教训

2025-05-010
OAAI